Pharmaceutical bosses today claimed Pfizer and AstraZeneca have now ironed out the kinks in their processes, which will result in less of the lumpy supply ministers have complained of.
UK Research and Innovation injects £118m into Scots firms and researchers scotsman.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from scotsman.com Daily Mail and Mail on Sunday newspapers.
PwC joins Medicines Manufacturing Innovation Centre The global professional services firm has signed on the newest partner in the collaboration, aimed toward promoting innovation in pharma manufacturing.
CPI, one of the founding partners in the Medicines Manufacturing Innovation Centre, has announced the signing of an agreement with PwC, making the company the latest partner in the collaborative effort. The Centre (established via a partnership among CPI, the University of Strathclyde, UK Research and Innovation, Scottish Enterprise and founding industry partners AstraZeneca and GSK) seeks to promote more innovative drug manufacturing processes and enable a more agile supply chain.
PwC and the existing partners will work to maximize technological opportunities across the pharma supply chain. Efforts include the organization’s flagship Grand Challenge projects, intended to advance emergent and disruptive technologies. The program is partially funded by
UK project looks to transform oligonucleotide medicines manufacturing UK catalyst organization, CPI, has announced the launch of a project that aims to revolutionize the manufacture of oligonucleotides, through a collaboration involving, among others, AstraZeneca, Exactmer, and Novartis.
The partners are looking to develop a scalable, sustainable and more cost-effective medicines manufacturing process for oligonucleotides: short strands of synthetic DNA or RNA. They will utilize their combined expertise across scale-up, analytics and process development to achieve those goals.
Oligonucleotides, which are short strands of synthetic DNA or RNA, can be used as medicines by interfering with how genes are expressed. While they have shown success in the treatment of rare diseases, this next-generation therapeutic class is now being explored to treat chronic diseases that affect much larger patient populations, said CPI.